Key result
Benidipine is linked to a ~14-mmHg systolic blood pressure reduction in hypertensive coronary syndrome patients.
Why the study?
The relationship between blood pressure reduction and improvement in angina-related health status during benidipine therapy remained uncertain.
Cohort (n=1,659)
Yes
Benidipine therapy in a real-world setting was associated with significant blood pressure reduction and clinically meaningful improvements in angina-related health status, though the symptomatic benefits appeared largely independent of the hemodynamic changes.
Answers are grounded in this paper and cite their sources.
May support benidipine in real-world hypertension/CCS; extends observational data but leaves causal effects open for RCTs.
Background: Benidipine is a long-acting calcium channel blocker used for the treatment of hypertension and chronic coronary syndrome. Although it effectively lowers blood pressure (BP), the relationship between BP reduction and improvement in angina-related health status during benidipine therapy remains uncertain. This study evaluated changes in BP and patient-reported angina-related health status in a large real-world cohort. Methods: This prospective, multicenter, observational cohort study included 1659 patients with hypertension and/or chronic coronary syndrome who underwent baseline clinical assessment before initiation of benidipine therapy and were reassessed after 3 months. Changes in systolic and diastolic BP and Seattle Angina Questionnaire-7 (SAQ-7) scores were evaluated. Multivariable linear regression analyses were performed to identify predictors of BP reduction and symptomatic improvement. A propensity score-matched analysis according to coronary artery disease (CAD) status was conducted to further explore differences in treatment response. Results: The mean age was 62.2 ± 12.2 years, and 54.0% of participants were women. Systolic BP decreased by 13.8 mmHg and diastolic BP by 6.7 mmHg (both p < 0.001). Mean SAQ-7 score increased by 8.1 points (p < 0.001), exceeding the established threshold for clinically meaningful improvement. Baseline SAQ-7 score showed the strongest association with change in SAQ-7, whereas baseline systolic BP was the strongest predictor of BP reduction. The correlation between changes in systolic BP and SAQ-7 was weak (r = 0.058, p = 0.023). In the propensity score-matched cohort (n = 732), BP reduction was similar regardless of CAD status, whereas improvement in SAQ-7 was greater in patients without obstructive CAD. Conclusions: In this multicenter real-world cohort, benidipine therapy was associated with significant BP reduction and clinically meaningful improvement in angina-related health status over 3 months. Symptomatic improvement showed only a weak association with BP reduction. These findings should be interpreted within the limitations of an observational study and warrant confirmation in controlled comparative studies.
No takes yet. Share an insight, caveat, or question.
Kunak et al. (2026) conducted a cohort in Hypertension and/or chronic coronary syndrome (n=1,659). Benidipine vs. Baseline (pre-treatment) was evaluated on Change in systolic blood pressure from baseline to 3 months (MD -13.8 mmHg, p=<0.001). Benidipine therapy was associated with a 13.8 mmHg reduction in systolic blood pressure and an 8.1-point increase in SAQ-7 score over 3 months in patients with hypertension and/or coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: